From 2009 to 2018, sodium stibogluconate (SS), a SHP inhibitor with a potent inhibitory effect on SHP-1, underwent several clinical trials and was proven to treat Leishmaniasis (Table 2). The gene discussed is NR0B2; the disease is leishmaniasis.